Page 36 - Gamida Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Recent clinical readouts could prove to be long-term growth catalysts for Novavax and Gamida Cell.

Gamida Cell raises $75m in convertible notes The funds will be used to support manufacturing, regulatory and commercial development activities for its advanced cell therapy treatment. Israeli advanced cell therapy company Gamida Cell (Nasdaq: GMDA) today announced the sale of $75 million of 5.875% exchangeable senior notes due in 2026 to funds managed by Highbridge Capital Management, a unit of JP Morgan. The initial exchange price of the notes of $17.70 per share represents a 50% premium over the closing price of Gamida Cell’s ordinary shares on February 12, and a 122% premium the public o...

Stem cells in bag in Gamida Cell’s Jerusalem lab, July 2017 (Shoshanna Solomon/TimesofIsrael) All of these “are meaningful results and represent potentially important advancements in care when considering the patient experience following transplant,” said Mitchell Horwitz, principal investigator and professor of medicine at the Duke Cancer Institute, in a statement released by the Jerusalem-based firm. The data was from the international, multi-center, randomized Phase 3 study of the drug, designed to evaluate the safety and efficacy of omidubicel in patients with high-risk hematologic ...

ARK invests $8m in Israeli cannabis co InterCure ARK's Israeli ETF bought a 2.4% stake in InterCure, which is worth NIS 775 million. ARK Exchange Traded Funds (ETF) has invested $8 million in Israeli cannabis company InterCure (TASE: INCR). This is part of ARK's recent spending spree on Israeli companies after setting up an Israeli ETF. InterCure is set to merge with a SPAC (special purpose acquisition company) on the Canadian stock exchange, and ARK now has a 2.4% stake in InterCure worth NIS 775 million. ARK bought the shares at NIS 6.46, similar to today's price. RELATED ARTICLES InterCure...

(2) INDIANAPOLIS (dpa-AFX) - Today's Daily Dose brings you news about KalVista's hereditary angioedema trial results, Heat Biologics' encouraging data from its phase II trial of HS-110 in non-small cell lung cancer, Gamida's presentation of full efficacy and safety results of Omidubicel in patients with hematologic malignancies and Neovasc regaining Nasdaq compliance. Read on. 1. Gamida's Presentation At TCT Meetings Catches Eyes Shares of Gamida Cell Ltd. (GMDA) were up over 60% at $16 in extended trading Tuesday, following the presentation of full efficacy and safety results of the company...